Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23931223 | 1.00 | CYP2C19 (0.41) | CYP2C19NFE2L2APPPTGS1PTGS2 | |
| SCHEMBL23931224 | 1.00 | CYP2C19 (0.41) | CYP2C19NFE2L2APPPTGS1PTGS2 | |
| SCHEMBL16612527 | 1.00 | CYP2C19 (0.41) | CYP2C19NFE2L2APPPTGS1PTGS2 | |
| SCHEMBL23931225 | 1.00 | CYP2C19 (0.41) | CYP2C19NFE2L2APPPTGS1PTGS2 | |
| SCHEMBL23931233 | 0.86 | APP (0.36) | CYP2C19NFE2L2APPPTGS1PTGS2 | |
| SCHEMBL23931235 | 0.86 | APP (0.36) | CYP2C19NFE2L2APPPTGS1PTGS2 | |
| SCHEMBL23931237 | 0.86 | APP (0.36) | CYP2C19NFE2L2APPPTGS1PTGS2 | |
| SCHEMBL23931226 | 0.85 | CYP2C19 (0.39) | CYP2C19MEN1KMT2ALMNAMAPT | |
| SCHEMBL23931228 | 0.85 | CYP2C19 (0.39) | CYP2C19MEN1KMT2ALMNAMAPT | |
| SCHEMBL23931227 | 0.85 | CYP2C19 (0.39) | CYP2C19MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415787-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2024-12-19 | — | — | US | claimed |
| EP-4397304-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | Shin Poong Pharmaceutical Co., Ltd. (KR) | 2024-07-10 | — | — | EP | claimed |
| CN-117897145-A | Composition for treating or preventing obesity or obesity-related liver diseases comprising verbenone derivatives | 韩国新丰制药株式会社 | 2024-04-16 | — | — | CN | claimed |
| US-10710951-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2020-07-14 | — | — | US | claimed |
| EP-2857007-B1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | UNIV KOREA RES & BUS FOUND (KR) | 2018-03-28 | — | — | EP | claimed |
| US-20170166505-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-15 | — | — | US | claimed |
| US-9603842-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-03-28 | — | — | US | claimed |
| US-20150148362-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-28 | — | — | US | claimed |
| EP-2857007-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | Korea University Research and Business Foundation (KR) | 2015-04-08 | — | — | EP | claimed |
| US-20240415787-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2024-12-19 | — | — | US | disclosed |
| EP-4397304-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | Shin Poong Pharmaceutical Co., Ltd. (KR) | 2024-07-10 | — | — | EP | disclosed |
| CN-117897145-A | Composition for treating or preventing obesity or obesity-related liver diseases comprising verbenone derivatives | 韩国新丰制药株式会社 | 2024-04-16 | — | — | CN | disclosed |
| US-10710951-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2020-07-14 | — | — | US | disclosed |
| EP-2857007-B1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | UNIV KOREA RES & BUS FOUND (KR) | 2018-03-28 | — | — | EP | disclosed |
| US-20170166505-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-9603842-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-03-28 | — | — | US | disclosed |
| US-20150148362-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-28 | — | — | US | disclosed |
| EP-2857007-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | Korea University Research and Business Foundation (KR) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166505-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | CASP3, DCX, BAX | CYP2C19 1307/4885NFE2L2 14/4885APP 96/4885 |
| US-10710951-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | CASP3, DCX, BAX | CYP2C19 1307/4885NFE2L2 14/4885APP 96/4885 |
| US-20240415787-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | SMAD3, TGFB1, TGFB2 | CYP2C19 2846/4885NFE2L2 345/4885APP 1814/4885 |
| US-20150148362-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | CASP3, DCX, BAX | CYP2C19 1307/4885NFE2L2 14/4885APP 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.